ENTA vs. SKYE
ENTA (Enanta Pharmaceuticals, Inc.) and SKYE (Skye Bioscience, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, ENTA returned -5.43%/yr vs -41.81%/yr for SKYE. Their 0.06 correlation means their historical movements had little consistent relationship.
Performance
ENTA vs. SKYE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ENTA achieves a -20.10% return, which is significantly higher than SKYE's -24.17% return. Over the past 10 years, ENTA has outperformed SKYE with an annualized return of -5.43%, while SKYE has yielded a comparatively lower -41.81% annualized return.
ENTA
- 1D
- -3.08%
- 1M
- -16.61%
- 6M
- -2.33%
- YTD
- -20.10%
- 1Y
- 77.22%
- 3Y*
- -12.24%
- 5Y*
- -21.49%
- 10Y*
- -5.43%
- ALL TIME*
- -1.05%
SKYE
- 1D
- -2.03%
- 1M
- -18.84%
- 6M
- -43.71%
- YTD
- -24.17%
- 1Y
- -83.33%
- 3Y*
- -52.63%
- 5Y*
- -57.01%
- 10Y*
- -41.81%
- ALL TIME*
- -49.21%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $1.83M | $2.27M | $2.92M | |
| $68.55K | $77.34K | $111.60K |
ENTA vs. SKYE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ENTA Enanta Pharmaceuticals, Inc. | -20.10% | 174.26% | -38.89% | -79.77% | -37.79% | 77.62% | -31.85% | -12.78% | 20.71% | 75.16% |
SKYE Skye Bioscience, Inc | -24.17% | -73.51% | 4.04% | -32.84% | -68.85% | 30.00% | -69.47% | -67.25% | 163.16% | -49.67% |
Correlation
The correlation between ENTA and SKYE is 0.02, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.02 |
Correlation (3Y) Balances recent behavior with more history. | 0.13 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.09 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.06 |
Correlation (All Time) Calculated using the full available price history since Apr 2, 2015 | 0.06 |
The correlation between ENTA and SKYE shifts across timeframes, from 0.02 (1 year) to 0.13 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
ENTA:
$366.39M
SKYE:
$19.98M
ENTA:
-$2.60
SKYE:
-$1.45
ENTA:
3.16
SKYE:
2.50
ENTA:
$69.21M
SKYE:
$0.00
ENTA:
$33.44M
SKYE:
-$180.01K
ENTA:
-$61.85M
SKYE:
$10.92M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ENTA vs. SKYE — Risk / Return Rank
ENTA
SKYE
ENTA vs. SKYE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Enanta Pharmaceuticals, Inc. (ENTA) and Skye Bioscience, Inc (SKYE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ENTA | SKYE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.43 | ||
| Sortino ratioReturn per unit of downside risk | +3.61 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 0.80 | +0.47 |
| Calmar ratioReturn relative to maximum drawdown | 1.94 | -0.96 | +2.90 |
| Martin ratioReturn relative to average drawdown | 3.44 | -1.15 | +4.59 |
Loading charts...
Drawdowns
ENTA vs. SKYE - Drawdown Comparison
The maximum ENTA drawdown since its inception was -96.63%, roughly equal to the maximum SKYE drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for ENTA and SKYE.
Loading charts...
Drawdown Indicators
| ENTA | SKYE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.63% | -99.96% | +3.33% |
Max Drawdown (1Y)Largest decline over 1 year | -34.30% | -88.03% | +53.73% |
Max Drawdown (3Y)Largest decline over 3 years | -78.51% | -96.84% | +18.33% |
Max Drawdown (5Y)Largest decline over 5 years | -95.62% | -98.58% | +2.96% |
Max Drawdown (10Y)Largest decline over 10 years | -96.63% | -99.84% | +3.21% |
Current DrawdownCurrent decline from peak | -90.03% | -99.96% | +9.93% |
Average DrawdownAverage peak-to-trough decline | -49.66% | -94.98% | +45.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.35% | 72.94% | -53.59% |
Volatility
ENTA vs. SKYE - Volatility Comparison
The current volatility for Enanta Pharmaceuticals, Inc. (ENTA) is 11.70%, while Skye Bioscience, Inc (SKYE) has a volatility of 14.37%. This indicates that ENTA experiences smaller price fluctuations and is considered to be less risky than SKYE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ENTA | SKYE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.70% | 14.37% | -2.67% |
Volatility (6M)Calculated over the trailing 6-month period | 34.43% | 53.78% | -19.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 108.78% | 103.06% | +5.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 73.65% | 130.59% | -56.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.73% | 136.04% | -75.31% |
Dividends
ENTA vs. SKYE - Dividend Comparison
Neither ENTA nor SKYE has paid dividends to shareholders.
Financials
ENTA vs. SKYE - Financials Comparison
This section allows you to compare key financial metrics between Enanta Pharmaceuticals, Inc. and Skye Bioscience, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ENTA and SKYE have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SKYE has higher volatility (14.37%) compared to ENTA (11.70%). In terms of maximum drawdown, ENTA dropped -96.63% vs SKYE's -99.96%.
ENTA currently has the higher Sharpe Ratio (0.61 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ENTA and SKYE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer